bioRxivImmunology
Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells
P. Mistry, C. S. Boddupalli, G. Belinsky, J. Gans, E. Teeple, T.-H. Nguyen, S. Mehta, L. Guo, M. Kramer, J. Ruan, H. Wang, M. Davison, V. DJ, B. Zhang, K. Klinger, S. Nair
Abstract
BackgroundNeuronopathic Gaucher Disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in Gba, and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features, however the role of Gba in individual cell types and involvement of microglia, blood derived macrophages and immune infiltrates in nGD pathology remains enigmatic. MethodsHere, using single cell resolution of mouse nGD brains, we found induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons. ResultsTargeted rescue of Gba in microglia and in neurons, respectively in Gba deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), concomitant with amelioration of neuroinflammation, reduced level of serum neurofilament light chain (Nf-L) and improved survival. The levels of bioactive lipid, GlcSph was strongly correlated with serum Nf-L and ApoE in nGD mouse models as well as GD patients. Gba rescue in microglia/macrophage compartment prolonged survival, that was further enhanced upon treatment with brain permeant inhibitor of glucosylceramide synthase, effects mediated via improved glycosphingolipid homeostasis and reversal of neuroinflammation involving activation of microglia, brain macrophages and NK cells. ConclusionsTogether, our study delineates individual cellular effects of Gba deficiency in nGD brains, highlighting the central role of neuroinflammation driven by microglia activation and the role of brain permeant small molecule glucosylceramide inhibitor in reversing complex multidimensional pathophysiology of nGD. Our findings advance disease biology whilst identifying compelling biomarkers of nGD to improve patient management, enrich clinical trials and illuminate therapeutic targets. FundingResearch grant from Sanofi Genzyme; other support includes R01NS110354.Yale Liver Center P30DK034989, pilot project grant.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of microglial GBA hampers the microglia-mediated anti-oxidant and protective response in neurons
Electra Brunialti, Alessandro Maria Villa, … Paolo Ciana·Journal of NeuroinflammationPeer-reviewed·Sep 22, 2021
- Glucocerebrosidase deficiency leads to neuropathology via cellular immune activation
Evelyn S. Vincow, Ruth E. Thomas, … Leo J. Pallanck·PLoS GeneticsPeer-reviewed·Nov 11, 2024
- Metabolic reprogramming and altered ATP content impair neuroprotective functions of microglia in β-glucocerebrosidase deficiency models
Electra Brunialti, Alessandro Maria Villa, … Paolo Ciana·Journal of NeuroinflammationPeer-reviewed·Nov 25, 2025
- Anti-inflammatory role of GM1 and modulatory effects of gangliosides on microglia functions
Danny Galleguillos, Qian Wang, … Simonetta Sipione·bioRxiv·Mar 4, 2020
- Patient-Specific Midbrain Organoids with CRISPR Correction Recapitulate Neuronopathic Gaucher Disease Phenotypes and Enable Evaluation of Novel Therapies
Yi Lin, Benjamin Liou, … Ying Sun·bioRxiv·Nov 6, 2025
- Gba1 deletion causes immune hyperactivation and microbial dysbiosis through autophagic defects
Magda Luciana Atilano, Alexander J. Hull, … Kerri J. Kinghorn·PLoS GeneticsPeer-reviewed·Dec 21, 2023